Next Article in Journal
Can Nebulised Colistin Therapy Improve Outcomes in Critically Ill Children with Multi-Drug Resistant Gram-Negative Bacterial Pneumonia?
Next Article in Special Issue
Drug Susceptibility Testing and Synergistic Antibacterial Activity of Curcumin with Antibiotics against Enterotoxigenic Escherichia coli
Previous Article in Journal
Polymyxins: To Combine or Not to Combine?
Previous Article in Special Issue
Antifungal Activity in Compounds from the Australian Desert Plant Eremophila alternifolia with Potency Against Cryptococcus spp.
Open AccessArticle

Rifampicin-Loaded Mesoporous Silica Nanoparticles for the Treatment of Intracellular Infections

1
School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, SA 5000, Australia
2
ARC Centre of Excellence in Convergent Bio-Nano Science & Technology, University of South Australia, Mawson Lakes, SA 5095, Australia
3
The Basil Hetzel Institute for Translational Health Research, Woodville, SA 5011, Australia
4
Research Centre for Infectious Disease, School of Biological Sciences, The University of Adelaide, Adelaide, SA 5000, Australia
*
Author to whom correspondence should be addressed.
Antibiotics 2019, 8(2), 39; https://doi.org/10.3390/antibiotics8020039
Received: 19 March 2019 / Revised: 3 April 2019 / Accepted: 5 April 2019 / Published: 11 April 2019
Infectious diseases remain a major burden in today’s world, causing high mortality rates and significant economic losses, with >9 million deaths per year predicted by 2030. Invasion of host cells by intracellular bacteria poses treatment challenges due to the poor permeation of antimicrobials into the infected cells. To overcome these limitations, mesoporous silica nanoparticles (MSNP) loaded with the antibiotic rifampicin were investigated as a nanocarrier system for the treatment of intracellular bacterial infection with specific interest in the influence of particle size on treatment efficiency. An intracellular infection model was established using small colony variants (SCV) of S. aureus in macrophages to systemically evaluate the efficacy of rifampicin-loaded MSNP against the pathogen as compared to a rifampicin solution. As hypothesized, the superior uptake of MSNP by macrophages resulted in an enhanced treatment efficacy of the encapsulated rifampicin as compared to free antibiotic. This study provides a potential platform to improve the performance of currently available antibiotics against intracellular infections. View Full-Text
Keywords: MSNP; intracellular infections; nanoparticles; antibiotics; SCVs; macrophages; rifampicin MSNP; intracellular infections; nanoparticles; antibiotics; SCVs; macrophages; rifampicin
Show Figures

Figure 1

MDPI and ACS Style

Subramaniam, S.; Thomas, N.; Gustafsson, H.; Jambhrunkar, M.; Kidd, S.P.; Prestidge, C.A. Rifampicin-Loaded Mesoporous Silica Nanoparticles for the Treatment of Intracellular Infections. Antibiotics 2019, 8, 39.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop